199730 — BioInfra Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeMicro CapValue Trap

Annual income statement for BioInfra Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	19,610	30,555	35,427	30,129	23,833
Cost of Revenue
Gross Profit	8,258	12,031	13,972	9,553	5,696
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	15,985	23,093	29,070	28,826	28,953
Operating Profit	3,625	7,463	6,358	1,302	-5,120
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	3,557	7,099	6,987	1,279	-5,876
Provision for Income Taxes
Net Income After Taxes	4,191	6,234	6,237	2,002	-3,976
Net Income Before Extraordinary Items
Net Income	4,191	6,234	6,237	2,002	-3,976
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	4,191	6,234	6,237	2,002	-3,976
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	874	1,294	1,316	426	-820
Dividends per Share